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1014-155 Functional Mitral Regurgitatlon in Patlents With Chronic 
Heart Failure: Reiatlonship to Left Ventricular and Left 
Atrlai Structural and Functional Parameters 
s, Klaus K. Witte, Simon D. Thackray, Mohammad F. Alamgir, Lindsey J. 
Goodge. Andrew L. Clark, John G. Cleland, The Univeraify of Hu//, Kingston-Upon-Hull, 
United Kingdom. 
This study was designed to explore the relationship between the severity of functional 
mitral regurgitation (MR) in patients with chronic heart failure (CHF) and indices of left 
ventricular (LV) and left atriai (LA) function obtained with the use conventional and new 
echocardiographic techniques. 
Methoda: 73 patients (age 69ilO years, 13 women) with clinically stable CHF (LV eiec- 
tion fraction <45%) underwent echocardlography including coiour tissue Doppler imaging 
(TDI). The presence and magnitude of MR was semi-quantitatively assessed by coiour 
Doppler flow mapping, and the MR jet area was used as a measure of MR severity. Miirai 
annular systolic (S,), early diastolic (E,) and late diastolic (A,,,) velocities were mea- 
sured using TDI at six sites in three apical views and averaged. 
Reaulta. Patients were divided into three subgroups (mild, moderate and severe MR). 
No significant difference in indices of LV remodeling (LV volumes and sphericity index) 
was found between the groups. LV ejection fraction was significantly higher in the mild 
MR group than in the remaining groups. The maximal LA dimension at end systoie was 
significantly higher, and LA active emptying fraction was significantly reduced in the 
severe MR group than in the two other groups. The majority of patients with severe MR 
demonstrated pseudonormal or restrictive patterns of LV diastolic filling. whereas non- 
restrfctive (impaired relaxation) patterns prevailed in the group of patients with mild MR. 
The severity of functional MR was proportional to E, and was inversely proportional to 
S, and A,. When multivariate analysis was performed, only Err,/& ratio and S, 
emerged as independent and additional predictors of the severity of MR. 
In concluafon, in patients with CHF due to LV systolic dysfunction. indices of global LV 
remodeling and LV ejection fraction do not appear to be closely associated with the 
severity of MR, while indexes reflecting LA morphology and pump function are signifi- 
cantly related to MR. There is a tendency towards more restrictive pattern of LV diastolic 
filling proportional to the severity of MR. Mitral annular velocities which are easy to mea- 
sure using colour TDI are important indicators of the severity of MR. 
were analyzed separately for symptomatic and asymptomatic patients and were com- 
pared with normal controls. 
Results. 61% of patients were in NYHA class I-II, 15% in class Ill, and 4% in class IV. 
Head failure occurred in 24% of patients with transposition of the great arteries (TGA) 
and a Mustard procedure, 34% of patients with L-TGA, 40% of Fontan palliated patients. 
Symptomatic patients had significantly lower maximal work load (496.46 +/- 265.26 vs. 
567.24 +/- 199.31 kilopond-meters, p&04), AT (11.3 t/- 3.5 vs. 13.2 +/- 4.9 ml/kg/min, 
p=O.O093). and V02 max (14.69 +/- 5.03 vs. 20.29 +I- 6.75 mi/kg/min, p < 0.00022). Sys- 
temic ventricular function (SVEF) in symptomatic vs. asymptomatic patients at rest and 
during exercise was, 33.42 +/- 15.67 vs. 46.66 +I- 13.42 (p < 0.00001) and 36.66 +/- 
16.71 vs. 53.33 +I- 14.06 (p < O.OCrgl). Mortality rate was 46% among symptomatic 
patients, and 5% among asymptomatic patients during follow-up. 
Conclusion. Patients with single or systemic right ventricles and heart failure symptoms 
have significant cardiovascular limitation compared to asymptomatic patients, who in turn 
have significant cardiovascular limitation compared to the control population. This study 
suggests the importance of identifying patients with single or systemic right ventricles at 
risk for heart failure and the importance of considering strategies to preserve ventricular 
function. 
1014-158 Hypothermia as an Indicator of Imminent Death in Late 
Stage Congestive Heart Failure 
Moein F. Vaseghi, Said Siadaty, Morteza Naghavi, Mohammad Madjid, $&M~J&& 
Casscells., Division of Cam’iology. University of Texas-Houston, Houston, Texas. 
1014-156 Nonexcitatory Cardiac Contractility Modulation in Heart 
Failure: influence of Stimulated Chamber on 
Hemodynamic and Mechanical Response 
wPaowne, Salvatore Rosanio, Daniel Burkhoff, Yuval Mika, Gabriele Vicedomini, 
Monica Tocchi, Vincenzo Santlneiii, Itzhak Shemer, David Prutchi, Waiid Haddad, 
Yehuda Snir, Shiomo A. Ben-Haim, San R&se/e University Hospital, Milano, /t&-/x 
Technion-Israel Institute of Technology Haifa, Israel. 
Numerous predictors of mortality in CHF patients have been described. but even in com- 
bination the sensitivity and specificity are modest. We noted in a retrospective case-con- 
trol study, that in-hospital CHF death was best predicted by hypothermia, lymphopenia, 
right and left ventricular failure, and hypotension. Here we sought to examine in a cohort 
study if temperature is an independent prognostic variable Methods: We investigated 
medical records of patients (pts) with an ICD code of CHF on their last hospital admission 
between Jan and Dee 96. 35 pts were excluded because of temperature (T) confound- 
ers. Factors affecting outcome were entered into a multiple regression model. Results: 
On admission the mean T of ail 291 pts was 97.3*1 .l “F. The mean T on admission of 
pts who sun/Ned (N=274) was 97.3+1.0 “F, and in the pts who died in hospital (N=17) T 
was 96.6i1.7 “F. An increase of 1 “F on admission correlated with an increase in iikeii- 
hood of survival of 76% (p=O.124). Tricuspid regurgitation (marker used for pulmonary 
hypertension and RV function) was a strong predictor (Exp(B) = 37, p= 0.037). Weaker 
predictors were systolic hypotension (Exp(B)=0.96, p=O.O4), female sex 
(Exp(B)=4.l,p=0.04), azotemia. and creatinine (Exp(B)=1.4, p=O.O03). but not sodium or 
% lymphocytes. Death was also predicted by VT but not by AF or RR variability. Conciu- 
sion: Our two studies using different design have identified hypothermia as a novel, pow- 
erful, univariate and multivariate predictor of in-hospital death of CHF patients. 
Background: Electrical currents applied during the action potential refractory period 
have been shown to modulate contractility in vitro and in viva. We assessed the influence 
of stimulated chamber on the hemodynamic and mechanical effect of these non-excita- 
tory cardiac contractility modulating (CCM) signal in patients with chronic heart failure. 
Methods: CCM signals were monophasic square-wave pulses with adjustable ampli- 
tude, duration and time delay from sensing of local electrical activity. Signals were 
applied to the LV through an epicardial vein (12 patients) or to the right ventricular (RV) 
septum endocardially (6 patients). Simultaneous LV and aortic pressures measurements 
were performed by a Millar catheter. Hemodynamics during right-sided DDD pacing was 
regarded as control condition. Results: With LV stimulation, 2 patients complained of 
chest discomfort at 10mA CCM amplitude, which was abolished at 6mA in one patient, 
while in the other a further reduction to 6mA was necessary. With RV stimulation, no 
symptoms occurred and it was possible to use 14mA CCM in all patients. Both LV and 
RV CCM stimulation enhanced dP/dt,,,,, to a similar degree (6.6* 5.4% and 6.6* 0.5%, 
respectively, PcO.01 vs control), with associated pulse pressure changes of tO.3i 7.2% 
and 10.6f. 1.4% (PcO.01 vs control). Echo color kinesis, a technique for quantifying glo- 
bal and regional systolic function, demonstrated an overall increase in the magnitude and 
velocity of contraction in both groups, expressed by significant (PcO.05) increase in glo- 
bal fractional area change in 56 of end-diastolic area (LV 22f5% vs. RV 23-t4%. P=NS) 
and peak ejection rate and shortening in time-to-peak ejection rate. The magnitude of 
regional systolic endocardiai motion was markedly enhanced near the CCM electrode, 
with a lesser but significant improvement in remote regions as well. Conclusions: Local 
CCM stimulation of LV or RV myocardium enhances global LV systolic performance to a 
similar degree. The right-sided approach may be associated with less symptoms and 
penit use of higher current amplitudes, which correlate with stronger contractile 
enhancement in experimental preparations. 
1014-158A Risk Stratification Using A Combinatlon of Cardiac 
Troponin T and Brain Natriuretic Peptkle After 
Optimized Treatment in Patients with Advanced Heart 
Failure 
Junnlchl, Masanori Nomura, Yuu Nakamura, Hiroyuki Naruse, Yoshihisa Mod, 
Toshikazu Ando, Hiroshi Kurokawa, Takeshi Kondo, Hi&hi Hishida, Fujita Health 
Universitv, Toyoake, Japan. 
1014-157 Heart Failure and Ventrlcuiar Dysfunction in Patients 
With Single and/or Systemic Right Ventricles 
mPiran, Gruschen Veldtman, Gary D. Webb, Peter P. Liu, Congenital Cardiac 
Centre and Heart B Stroke/RL Center of Excellence, University of Toronto, Toronto, 
Ontario, Canada. 
Background, and Objectives. Previous studies have shown an increased incidence of 
congestive heart failure and mortality in patients with single and/or systemic right ventri- 
cles. We sought to characterize ventricular dysfunction as well as overt heart failure in 
this population. 
Methods. 193 consecutive adult patients with a single and/or systemic right ventricle 
were identified from the database of the University of Toronto Congenital Cardiac Centre 
for Adults (UTCCCA). The patients were assessed with gated radionuciide angiography 
(137) or 2-D echocardiographic (193). Hospital records were reviewed for the following 
clinical endpoints of maximal oxygen uptake (V02 max), anaerobic threshold (AT), a his- 
tory of heart failure, and the presence of heart failure on chest radiograph (CXR). Data 
Background: The aim of this study was to evaluate whether repetitive measurements of 
cardiac troponin T (TnT) and brain natriuretic peptide (BNP) before and after optimized 
treatment are useful for risk stratification in patients (pts) with congestive heart failure 
(CHF). Methods: Levels of TnT and BNP and left ventricular ejection fraction (EF) were 
measured both on admission and on discharge in 93 consecutive pts hospitalized for 
worsening CHF (mean age 69 yrs, NYHA class ii in 24 pts, Iii in 46, IV in 23). Pts were 
monitored for a mean follow-up period of 272 days after discharge. Results: The detec- 
tion rate of TnT (>O.Ol @ml), TnT and BNP levels, EF and NYHA class on discharge 
(mean length of hospital stay 36 days) were improved compared with the value on 
admission (detection rate of TnT: 39 YS 60%: TnT: 0.03 vs 0.07; BNP: 267 vs 725 pg/ml; 
EF: 45 vs 40%; NYHA class: 2.2 vs 3.0; p<O.Oi). During the follow-up period, there were 
36 (39%) cardiac events (9 cardiac deaths and 27 readmissions for worsening CHF). In a 
stepwise Cox regression analysis including TnT, log BNP, EF and NYHA class on admis- 
sion and discharge, age and sex, TnT (p=O.o003) and log BNP (p=O.O4) on discharge 
were independent predictors of cardiac event. Using discharge values of TnT (> or < 
0.01: T+ or T-) and BNP (> or < 160: B+ or B-) determined by ROC curves, the pts were 
March 6,2002 
JACC March 6, 2002 ABSTRACTS - Cardiac Function and Heart Failure 131A 
divided into 4 subgroups (Table). Conclusion: Measuring the combination of TnT and 
BNP after optimized treatment may be valuable for risk assessment of cardiac mortality 
and morbiditv in CHF pts. 
-Risk etr&cation using discharge values of TnT and BNP 
Subgroup I (T-/8-) n=37 II (l-/B+) n=20 Ill (T+/B-) n=9 IV (T+/B+) n=27 
Cardiac death 0 (0%) 0 (0%) 2 (22%) 7 (26%) 
Cardiac event 5 (14%) 6 (30%) 4 (44%) 21 (78%) 
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1015-137 Compensated Cardiac Hypertrophy in Endothelial Nitric 
Oxide Synthase Knockout Mice 
Michael P. Fl&&y, Maria Brown, Hitoshi Takano, lngrid L. Grupp, Jo El Schultz, Sidney 
Murphree, W. Keith Jones, University of Cincinnati, Cincinnati, Ohio, University of 
Louisville, LouisviNe. Kentucky 
Background’. It is well documented that endothelial nitric oxide synthase (eNOS) homozy- 
gous knockout mice (eNOS+) develop sustained arterial hypertension. Because of con- 
troversy over the development of cardiac pathophysiology in these mice, we undertook to 
investigate the cardiac functional and biochemical affects of chronic eNOS ablation. 
Methods: We examined steady state levels of molecular markers of cardiac hypeltrophy 
and heart failure in male eNOS.” and control mice at 18-20, 27-30, 40 and 52 weeks of 
age. Histological examination at 40 weeks of age and cardiac functional analysis using 
the isolated work performing heart preparation were perlormed at 52 weeks of age. 
Results: Hearts from eNOS+ mice exhibited concentric left ventricular hypertrophy, multi- 
focal replacement fibrosis and evidence of myocyie degeneration/death. As mice aged, 
re-induction of atrial natriuretic factor (ANF) and a-skeletal-actin mRNA correlated posi- 
tively with the degree of cardiac hypertrophy. Significant increases in cardiac expression 
of tumor necrosis factor-a (TNF-a) mANA and protein were detected at 27-30 weeks. 
Sarcoplasmic reticulum Ca’+-ATPase (SERCA2a) transcript levels were markedly 
decreased at 27-40 weeks, whereas heads of eNOS”- mice 52 weeks of age demon- 
strated normalized SERCA2a and slightly decreased phospholamban protein levels. 
Although hearts of eNOS’. mice at 52 weeks of age demonstrated no deficit of baseline 
function, there was a blunted response to P-adrenergic stimulation indicative of reduced 
contractile reserve. 
Conclusions: Although eNOS+ mice exhibit myocardial remodeling, including re-induc- 
tion of cardiac fetal genes and dysregulation of TNF-a and SERCA2a, there is no pro- 
gression to failure before 52 weeks of age and in fact these hearts are hypercontractile. 
An increased ratio of SERCA2a protein to phospholamban protein at this timepoint sug- 
gests a mechanism for the long-term physiological compensation that occurs in eNOS”. 
hearts. 
1015-138 New Mutation in Lamin A/C Gene Associated With 
Severe Dilated Cardiomyopathy 
B. Lorenzo Monserrat, Sandra Barral, Rafael Laredo, Beatriz q  ouzas, 
Marisa Crespo. Alfonso Castro-Beiras, Hospital Juan Canalejo, A Corufia, Spain, 
lnstituto de Ciencias de la Salud, A Corufia, Spain. 
Background: Idiopathic Dilated Cardiomyopathy (DCM) is familial in about 30% of the 
cases. Lamin AJC mutations have been identified for causing familial DCM, frecuently 
associated with conduction system disease. We repon here a novel lamin A/C mutation 
with features of severe dilated cardiomyopathy. 
Methods: After informed consent, we studied the lamin A/C gene in 17 patients of 14 dif- 
ferent families with familial DCM. DNA was isolated from frozen blood samples and cod- 
ing regions of lamin A/C were PCR amplified, studied by SSCP and cycle sequenced. 
Results:Three members of one of the families (mother and her two female identical 
twins) developed severe DCM and required cardiac transplantation at 36, 18, and 20 
years old respectively. The father of the index case had died suddenly at 52 years old. At 
diagnosis, the mother was on atrial fibrillation with slow ventricular response. No conduc- 
tion disturbance was present in the twins. 
A new mutation (Arg349Leu) was identified in exon 6 in the three patients. This mutation 
was not present in 22 unaffected relatives and in more than 100 healthy controls. This 
mutation affects a highly conserved region identical in Xenopus laevis. Gallus gallus. 
Rattus norvegicus and humans. 
Conclusions: The Arg349Leu mutation in LMNA A/C gene is associated with a severe 
form of DCM. 
1015-139 Cyclosporine A Treatment Decreases Left Ventricular 
Mass in Mice Expressing a FHC-Linked Troponin T 
(179N) Mutation 
Bioern C. Knollmann, Syevda G. Sirenko, James D. Potter, Kenneth Horton, Neil J. 
Weissman, Georgelow Universify School of Medicine, Washington, Dist. of Columbia, 
Washington Hospital Center, Washington, Dist. of Columbia. 
Cyclosporine A (CyA) prevents cardiac hypertrophy in several animal models, and has 
been proposed as treatment for Familial Hypertrophic Cardiomyopathy (FHC). But with 
the recent report that CyA administration increased cardiac hypertrophy and mortality in 
a mouse model of FHC (aMHC+/403), proposed clinical studies with CyA were aban- 
doned. Because the CyA effect could be specific to this particular mouse model, we 
examined the effect of CyA in a different murine FHC model expressing a troponin T 
(179N) mutation. Methods: Mice expressing human wild-type (Tg-WT), mutant (Tg-l79N) 
Troponin T and non-transgenic littermates (Non-Tg) were treated with CyA (18mqkgl 
day) or vehicle for 4 weeks. LV dimensions, mass and function were measured with 
serial echocardiography in blinded fashion. Results: All mice tolerated CyA treatment. 
LV wall thickness and mass significantly decreased in CyA-treated Tg-l79N mice corn- 
pared to all other groups (table). Systolic function was unchanged. On sacrifice, heart to 
body weight ratio was significantly decreased in CyA-treated compared to vehicle-treated 
Tg-l79N mice, (3.3ztt.lmg/S vs. 3.6M.lmg/g. pc.05). No significant differences in tissue 
histology were found. Blood CyA levels were 453+124 nglml. Conclusion: Unlike in 
mice expressing a a-myosin heavy chain FHC mutation, CyA treatment reduced LV 
mass in mice expressing a FHC-linked Troponin T mutation. Thus, any effect of CyA 
treatment should not be generalized across different FHC-linked mutation or models. 
Effect of CyA treatment on LV-mass (means+ee) 
Genotwe n Treatment Baseline (ma) 4 weeks (ma) 
Tg-l79N 
Tg-l79N 
Tg-WT 
Non-Ta 
7 CYA 84t3 72+4” 
7 Vehicle 85t6 116*4 
6 CYA 1 oot3 11255 
6 CvA 67*3 111*6 
1015-140 Effect of Estrogen on Angiotensin Receptors, Matrix 
Metalloproteinases, and Left Ventricular Mass in a 
Transgenic Mouse Model of Human Hypertrophic 
Cardiomyopathy 
Edith Speir, zurxiylc, Kazuyo Takeda, Victor J. Ferrans. Mariappan Muthuchamy, Lameh 
Fananapazir, National Heart, Lung and Blood Institute, Bethesda, Maryland, Texas ABM 
Univarsify, Co//ege Station, Texas. 
Background: Mutahons in a-tropomyosin (Aspl75Asn) can cause familial hypertrophic 
cardiomyopathy (FHCM). Estrogen has been shown to be cardioprotective in several dis- 
eases. This study was designed to determine whether estrogen in physiological doses 
can modify left ventricular (LV) function and hypertrophy by attenuating release of matrix 
metalloproteinases (MMPs) and by regulating angiotensin receptors (AT,) in a transgenic 
mouse model (TGM) expressing Aspl75Asn. 
Methods: TGM and nontransgenic cohorts (NTGM) (20 each) were ovariectomized (0~). 
Slow-release (90 days) estrogen pellets were implanted in 10 mice of each group; the 
other 10 received placebo. Echocardiograms were performed in awake mice at 2 weeks 
after ov (baseline) and after 3 months of daily treadmill exercise. LV mass was assessed 
from M-mode tracings. Mice were then euthanized and some hearts were perfusion-fixed 
and embedded in paraffin, for sectioning; others were processed for frozen sections and 
tissue extracts. lmmunohistochemical staining and immunoblotting were performed. 
Results: Intact TGM and NTGM had LV masses of 77 and 49 mg. and placebo-treated 
and estrogen-treated OY TGM had LV masses of 79 and 60 mg. respectively (p-zO.05, for 
both comparisons). AT-1 receptors, MMP-3 and MMP-13 were increased in untreated ov 
TGM compared to estrogen-treated OY TGM. 
Conclusions: Estrogen replacement significantly reduced LV mass, AT-1 receptors and 
MMP-3 and MMP-13 in a model of FHCM. These findings suggest that estrogen can reg- 
ulate expression of genes involved in matrix metabolism and cardiac fibrosis, which are 
of clinical importance in human patients with FHCM. 
1015-l 59 Determinants of Exercise Capacity in Hypertrophic 
Cardiomyopathy: The Role of Left Ventricular Outflow 
Tract Obstruction 
MunmohanS.Virdee, Yoshihisa Matsumura, Sami Firoozi, Perry M. Elliott, William J. 
McKenna, St George’s Hospital Medical School, London, United Kingdom. 
Background: The influence of left ventricular outflow tract obstruction (LVOTO) on exer- 
cise capacity in patients (pts) with Hypertrophic Cardiomyopathy (HCM) is poorly under- 
stood. 
Methods: 86 pts with HCM (43 +14yrs, 73% symptomatic) underwent upright bicycle 
ergomehy with expiratory gas analysis and echocardiography. Oxygen consumption at 
peak exercise (pkVOP), anaerobic threshold (atV02); 02 pulse at peak exercise (pkO2 
pulse), anaerobic threshold (at02 pulse); and peak workload are expressed as percent- 
age of predicted values. 
Results: 37 pts with resting LVOTO >=30mmHg (58 *2OmmHg, group A), had a lower 
pkVO2 than those without resting LVOTO, 65 219 vs 74 *19%, p=O.O3. In pts without 
resting LVOTO, pkVO2 correlated with peak exercise LVOTO (wO.43, p=O.O03) and 
change in LVOTO during exercise (r=O.44, p=O.O02). Of 49 pts without resting LVOTO. 
16 developed LVOTO >SOmmHg during exercise (group Bi), 33 did not (group Bn). Peak 
exercise LVOTO was lower in group Bi than group A (48 i21 vs 81 r27mmHg. p<O.OOl). 
Table 1. 
There was no difference between the 3 groups for peak heart rate and respiratory quo- 
